Acute Myeloid Leukemia
Conditions
Keywords
Acute Myeloid Leukemia, Aged of 65 to 79 years, Older Patients with Acute Myeloblastic Leukemia
Brief summary
A Randomized Multicenter Phase III Study to Evaluate the Role of All-trans Retinoic Acid (ATRA) in Combination with Induction Chemotherapy, or Azacitidine and Idarubicin as salvage therapy and Idarubicin with Cytarabine or Azacitidine as Maintenance Therapy in Older Patients with Acute Myeloblastic Leukemia (AML). To compare the outcome of elderly patients with newly-diagnosed AML treated with standard induction chemotherapy and post-remission therapy, in only patients in CR, with either azacitidine or cytarabine combined to idarubicin +/- ATRA and salvage therapy with azacitidine combined to idarubicin +/- ATRA.
Detailed description
Induction therapy : First randomization (R1) at baseline : ATRA versus no ATRA. Salvage therapy : No conventional salvage therapy is planned. Patients who will not achieve CR, according to IWG criteria after induction will be treated with 3 courses of azacitidine and idarubicin +/- ATRA combination, if eligible for further treatment. Followed by 3 identical courses and 6 courses of maintenance by azacitidine alone to be delivered every 28 days, in those patients reaching CR or PR after 3 courses (evaluation of response from 28 to 56 days from course 3). Randomization R2: type of maintenance: Response to induction will be evaluated 2 weeks after myeloid recovery, just before first consolidation course, due use of to pegfilgrastim, lenograstim or filgrastim during induction. Responses will be classified according to the Revised Recommendations of the IWG for AML. Patients in CR only will be subjected to a second randomization R2 as follows 6 courses of combined chemotherapy, will be delivered as outpatients, ATRA according to R1 randomization.
Interventions
DRUGVesanoid (ATRA)
45 mg/m2/day in two divided doses from D8 to D28
75 mg/m2/12h SC from D1 to D5
DRUGCYTARABINE
Cytarabine : 60 mg/m2/12h SC from D1 to D5
Sponsors
Assistance Publique - Hôpitaux de Paris
Acute Leukemia French Association
Study design
Allocation
RANDOMIZED
Intervention model
PARALLEL
Primary purpose
TREATMENT
Masking
NONE
Eligibility
Sex/Gender
ALL
Age
65 Years to 79 Years
Healthy volunteers
No
Inclusion criteria
1. Aged of 65 to 79 years 2. With a morphologically proven diagnosis of AML according to WHO classification either de novo or AML with myelodysplasia related changes 3. Not previously treated for AML 4. Signed informed consent.
Exclusion criteria
1. APL in the WHO classification. 2. Ph1-positive AML or prior Ph1-positive disease 3. AML evolving from a prior MPN in the WHO 2008 classification. 4. Prior treatment with chemotherapy or radiotherapy for another tumor 5. Prior tumor, if not stable for at least two years, except in-situ carcinoma and skin carcinoma 6. Prior advanced malignant hepatic tumor 7. ECOG Performance Status Score \> 2 8. Creatinine level more than 2x's the upper limit of the normal range (ULN) at the laboratory where the analysis was performed, except if AML-related. 9. Total serum bilirubin more than 2x's the ULN at the laboratory where the analysis was performed, except if AML-related. 10. AST (SGOT) or ALT (SGPT) more than 2.5x's the ULN at the laboratory where the analysis was performed, except if AML-related 11. LVEF less than.55 or equivalent by doppler echocardiography 12. Known intolerance to Azacitidine, mannitol, retinoids 13. Positive serum test for HIV and HTLV-1 14. NYHA Grade 3/4 cardiac disease . 15. Severe infection at inclusion time. 16. Psychiatric disease or an history of non-compliance to medical regimens or patients considered potentially unreliable. 17. Absence of health care insurance (affiliation à un régime de Sécurité Sociale) 18. Participation to any study requiring informed consent
Design outcomes
Primary
| Measure | Time frame |
|---|---|
| For randomization R1, the primary endpoint is Event-free Survival (EFS) | 2-year EFS |
| For randomization R2, the primary endpoint is disease free survival (DFS) | 2-year DFS |
Secondary
| Measure | Time frame |
|---|---|
| Overall survival | 2 years |
| Effects on relapse rates of ATRA and maintenance, with respect to cytogenetics risk groups, subtypes of AML and mutational status (FLT3, MLL), and biomarkers | 2 years |
| Assess the safety of combination ATRA + chemotherapy or idarubicin-azacitidine courses and of maintenance with azacitidine | 2 years |
| Response rate to azacitidine idarubicin +/-ATRA combination after intensive chemotherapy failure and identification of possible predictors of response to this therapy | 2 years |
| Complete Response (CR) rate | 2 years |
Countries
France
Outcome results
None listed